



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Antici	pated Classific of this Applic					Attorney's Docket No.:	
	Class	Subc				Jnit: <u>1805</u>		
	FILE	D BY EXPRES	S MAIL					
	Wash	Commissione nington, D.C. 2 FWC (if unde	20231	and Trac	lemarks			
	Sir:							
	This is a request for filing a CONTINUATIONX _ DIVISIONAL CONTINUATION-IN-PART application under 37 CFRX1.60 37 CFR 1.62, of pending prior application Serial No. 08/574,443 filed on December 15, 1995 of Elazar Rabbani et al Inventor(s)							
1	for:							
	NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING							
-	COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES Title of Invention							
	1.	X				application, as it as a true cop	originally filed and an	
	2.	X	1.27 estab	lishing sr	nall entity st	t under 37 CFF atus in the pric still applicable	r application is	
	3.	X	The filing f	ee is cald	culated as fo	llows:		

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT									
					R/	ATE		F	EE
	Number Filed		Number Extra		Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	1	=	0	х	\$ 11	\$ 22	=	\$ 395	\$
Independent Claims	1	=	0	х	\$ 41	\$ 82	=	\$ 0	\$
Multiple Dependent Claims Presented:Yesx_ No					\$ 135	\$ 270		\$	\$
If the difference in Col. 1 is less than zero, enter					in Col.2	BASIC FEE		\$ 395	\$
								\$ 395	\$

EXPRESS MAIL CERTIFICATE

Express Mail Label No EM449423938

Deposit Date

November 25,1997

I hereby certify that this paper and the attachments herein are being deposited with the United States. Postal Service Teapress Mail Post Office to Addressee service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patients and Tradamarks, Washington DC 2021

Ronald C. Fedus

Dose

Dose

Reg. No. 32,567

Attorney's Docket No. Enz-53 (DIV 4)

Elazar Rabbanı et al. Serial No.: 08/574,443 Herewith

Filed:

Page: 2 (Request for a Continuation Application Under 37 C.F.R. 1.60 -

November 25, 1997)

	4.	X	The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed.
		X	Any additional filing fees required under 37 CFR 1.16.
		X	Any patent application processing fees under 37 CFR 1.17.
	5.	X	The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. <u>05-1135</u> . A duplicate copy of this sheet is enclosed.
			 X Any patent application processing fees under 37 CFR 1.17. The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b). Any filing fees under 37 CFR 1.16 for presentation of extra claims.
¥	6.		A check in the amount of \$ is enclosed.
	7.	X	Cancel claims 25-244
	8. 	1	Amend the specification being before the first line of the sentence: This is a fontinuation, X divisional, continuation-in-particular Serial No. 08/574,443, filed on December 15, 1 55.
	9. —		Transfer the drawings from the prior application.
	10.	X	Informal X Formal drawings are enclosed.
	11.		Abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
	12.		Priority of application Serial No filed on is claimed under 35 U.S.C. 119. The certified copy of the priority application has been filed in prior application Serial No filed
	13.	X	The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. [A copy of the originally submitted Assignment and the Notice of Recordation are enclosed herewith.]
	14.	X	A preliminary amendment is enclosed.

Elazar Rabbani et al. Serial No.: 08/574,443 Filed: Herewith

Page: 3 (Request for a Continuation Application Under 37 C.F.R. 1.60 -

November 25, 1997)

15.	X	The power of attorney in the prior application is to: Ronald C. Fedus, Reg. No. 32,567, and John J. Santalone, Reg No. 32, 794.		
		(a) <u>X</u>	The power appears in the original papers in the prior application.	
		(b)	Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.	
		(c)	A copy of a new substitute power of attorney is enclosed.	
		(d)	Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)	
			Ronald C. Fedus, Esq. Enzo Diagnostics, Inc. c/o Enzo Biochem, Inc. 527 madison Avenue (9th Floor) New York, New York 10022	
16.	X	Also accomp Unintentiona 1.137(b).	panying this Request is a Petition to Revive An ally Abandoned Application Under 37 C.F.R.	
17.	X	I hereby veri application S	fy that the attached papers are a true copy of prior Serial No	
18.		unintentional the date that <u>Action</u> was o Request For Petition to Re 37 C.F.R. 1. With the expe	pplication (Serial No. 08/574,443) was ly abandoned after 2/25/97 , which was a response to the 11/25/96 Office riginally due. As noted under No. 16 above, this a Continuation Application is accompanying the evive an Unintentionally abandoned Application Under 137(b), along with the requisite petition fee therefor. ected granting of the Petition, the parent application ding with the filing of this new continuation application.	

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States